*95% CI: 65%, 82%; N=101.
CI=confidence interval; CR=complete response; ORR=objective response rate.

Please see Summary of Product Characteristics and Risk Minimisation Measures materials for full details on managing adverse reactions.
References: 1. Jacobson CA, et al. Poster presented at: American Society of Hematology (ASH) Virtual Annual Meeting and Exposition; December 5-8, 2020; San Diego, CA. Accessed January 25, 2021. 2. YESCARTA® SmPC, July 2020. YESCARTA, the Yescarta logo, KITE, and the Kite logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc. All other trademarks referenced herein are the property of their respective owners. © 2021 Kite Pharma, Inc. All rights reserved. ADMP1132 05/2021

In Israel, YESCARTA is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
Limitation of Use : YESCARTA is not indicated for the treatment of patients with primary or secondary central nervous system lymphoma.
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions to the Ministry of Health- Department of risk
management: https://sideeffects.health.gov.il/.
Adverse reactions may also be reported directly to the manufacturer of the suspected product. Adverse reactions related to Gilead products may be reported directly to Gilead via details below.
Telephone: 09-8802050
IL-YES-0016